Michael G M Derks

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4750370/publications.pdf

Version: 2024-02-01

933447 1199594 13 253 10 12 citations h-index g-index papers 13 13 13 268 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Science Translational Medicine, 2019, 11 , .	12.4	83
2	A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clinical Therapeutics, 2009, 31, 586-599.	2.5	24
3	<i>In vitro</i> and <i>in vivo</i> assessment of the effect of dalcetrapib on a panel of CYP substrates. Current Medical Research and Opinion, 2009, 25, 891-902.	1.9	23
4	Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drugâ€Drug Interactions. Journal of Clinical Pharmacology, 2010, 50, 1188-1201.	2.0	20
5	Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects. Clinical Drug Investigation, 2011, 31, 325-335.	2.2	18
6	Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects. Atherosclerosis, 2011, 219, 761-767.	0.8	17
7	Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. European Journal of Clinical Pharmacology, 2010, 66, 775-783.	1.9	16
8	No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opinion on Investigational Drugs, 2010, 19, 1135-1145.	4.1	16
9	Effects of Food Intake on the Pharmacokinetic Properties of Dalcetrapib: Findings From Three Phase I, Single-Dose Crossover Studies in Healthy Volunteers. Clinical Therapeutics, 2011, 33, 754-765.	2.5	16
10	Lack of clinically relevant drug–drug interactions when dalcetrapib is coâ€administered with ezetimibe. British Journal of Clinical Pharmacology, 2010, 70, 825-833.	2.4	12
11	Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers. Expert Opinion on Investigational Drugs, 2021, 30, 893-901.	4.1	5
12	Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers. Advances in Therapy, 2020, 37, 4720-4729.	2.9	3
13	Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects. Clinical Drug Investigation, 2011, , 1.	2.2	O